|1.||Xu, Wei: 7 articles (10/2015 - 03/2011)|
|2.||Bedford, Mark T: 6 articles (12/2015 - 09/2006)|
|3.||Wang, Lu: 4 articles (10/2015 - 01/2014)|
|4.||Zhao, Zibo: 4 articles (10/2015 - 01/2014)|
|5.||Yu, Menggang: 3 articles (01/2015 - 01/2014)|
|6.||Cheng, Donghang: 3 articles (07/2011 - 09/2006)|
|7.||Zeng, Hao: 2 articles (10/2015 - 05/2013)|
|8.||Wilke, Lee G: 2 articles (01/2015 - 01/2015)|
|9.||Mahajan, Aparna: 2 articles (01/2015 - 01/2015)|
|10.||Sherer, Nathan M: 2 articles (01/2015 - 01/2015)|
|1.||Breast Neoplasms (Breast Cancer)
05/10/2013 - "We previously showed that twofold overexpression of CARM1 in MCF7 breast cancer cells increased the expression of ERα-target genes involved in differentiation and reduced cell proliferation, thus leading to the hypothesis that activating CARM1 by chemical activators might be therapeutically effective in breast cancer. "
07/01/2013 - "Outcome analyses indicate that CARM1 expression is an independent predictor of shorter breast cancer-specific survival and disease-free interval in the whole series and in the ER-positive subgroup. "
01/01/2015 - "This study also demonstrates no obvious association of CARM1 isoform expression and clinical correlates in breast cancer. "
01/01/2015 - "Differential CARM1 Isoform Expression in Subcellular Compartments and among Malignant and Benign Breast Tumors."
01/01/2015 - "Correction: differential CARM1 isoform expression in subcellular compartments and among malignant and benign breast tumors."
07/01/2013 - "This study aims to investigate the clinical and biological importance of CARM1 protein expression in a large (1,130 patients), well-characterised and annotated series of invasive breast cancers using tissue microarrays and immunohistochemistry. "
01/01/2010 - "The goal of this study was to confirm the pattern of expression of CARM1 in human tumors and determine the mechanism of action in CARM1 overexpressed tumors. "
02/01/2014 - "Only CARM1 expression was found to be correlated with tumor differentiation and neither CARM1 nor PRMT1 expression was correlated with survival. "
02/01/2014 - "CARM1 and PRMT1 correlated in healthy but not tumor tissue. "
01/01/2014 - "CARM1 and BAF155: an example of how chromatin remodeling factors can be relocalized and contribute to cancer."
|3.||Colorectal Neoplasms (Colorectal Cancer)
01/01/2010 - "Further studies using surgical specimens demonstrated that CARM1 was highly overexpressed in 75% of colorectal cancers (49 out of 65) but not in the androgen-independent PCa. "
05/01/2011 - "In colorectal cancer cells with constitutively high Wnt/β-catenin activity, depletion of CARM1 inhibits expression of endogenous Wnt/β-catenin target genes and suppresses clonal survival and anchorage-independent growth. "
05/01/2011 - "A coactivator role of CARM1 in the dysregulation of β-catenin activity in colorectal cancer cell growth and gene expression."
01/01/2010 - "Differential CARM1 expression in prostate and colorectal cancers."
01/01/2010 - "The tissue microarray showed that CARM1 was particularly overexpressed in the colorectal cancers while CARM1 expression was not prevalent in the prostate and breast cancers. "
07/01/2004 - "The authors found that overexpression of CARM1 was involved in the development of prostate carcinoma as well as androgen-independent prostate carcinoma. "
07/01/2004 - "Since CARM1 is functionally different from most other transcriptional coactivators of the AR, it may serve as a new target for the treatment of hormone-independent prostate carcinoma."
07/01/2004 - "Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status."
07/01/2004 - "The expression of CARM1 in normal prostate epithelium, high-grade prostatic intraepithelial neoplasia (PIN), and prostate carcinoma tissue was examined in 66 previously untreated patients with prostate carcinomas, as well as 12 patients with hormone-independent prostate carcinoma, using immunohistochemical methods. "
10/01/2013 - "In the present study, we found that the expression of coactivator-associated arginine methyltransferase 1 (CARM1), a histone methyltransferase that functions as a cofactor for nuclear hormone receptors and several transcription factors, was elevated in adenomas and aberrant in carcinomas during hepatocellular carcinogenesis. "
|5.||Motor Neuron Disease (Primary Lateral Sclerosis)
|1.||coactivator-associated arginine methyltransferase 1
|3.||Transcription Factors (Transcription Factor)
|4.||Protein Isoforms (Isoforms)
|5.||Cytoplasmic and Nuclear Receptors (Nuclear Receptors)
|6.||Steroid Receptors (Steroid Receptor)
|1.||Drug Therapy (Chemotherapy)